|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
$299,979
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
$49,999
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
3R43CA217502-01A1S1
|
$2,000
|
$660
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
$1,111,364
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
$53,716
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
$260,282
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$109,384
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
IGF::OT::IGF IGF::OF::IGF- PHASE III TRIAL OF CARBON ION THERAPY
|
261201500022C
|
$462,158
|
$462,158
|
GUHA, CHANDAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-06
|
$346,525
|
$69,305
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer
|
5R01CA211176-02
|
$362,569
|
$362,569
|
ELSEA, SARAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$4,755
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$10,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$5,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$128,125
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-04
|
$473,915
|
$473,915
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
|
5U01CA214254-02
|
$1,020,224
|
$1,020,224
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
$25,432
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
$8,650
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
$438
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Multifunctional immunoPET tracers for pancreatic and prostate cancer
|
7R01CA174294-06
|
$377,890
|
$188,945
|
WU, ANNA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Molecular Mechanisms of BRCA1-Dependent DNA Damage Response and Tumorogenesis
|
5R01CA132755-11
|
$382,500
|
$126,225
|
YU, XIAOCHUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Identification of Plasma- and Exosome-Based Protein Biomarkers for Early Detection of Pancreatic Cancer Using SOMAscan Technology
|
1R21CA218960-01A1
|
$228,375
|
$228,375
|
LIBERMANN, TOWIA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Isolation and Assessment of Blood-Circulating Cancer Exosomes with LSS and SERS Lab on a Chip Optical Spectroscopic Instrument
|
1R01CA218382-01A1
|
$668,549
|
$668,549
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Single-molecule mechanical detection of protein and microRNA cancer biomarkers
|
5R21CA212827-02
|
$248,117
|
$248,117
|
WONG, WESLEY
|
BOSTON CHILDREN'S HOSPITAL
|
|
Development of a novel Antibody Drug Conjugate for the treatment of pancreaticcancer
|
1F30CA220843-01A1
|
$49,524
|
$49,524
|
GROMISCH, CHRISTOPHER
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A Prospective Investigation of the Oral Microbiome and Pancreatic Cancer
|
5U01CA187508-04
|
$430,565
|
$430,565
|
PALMER, JULIE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
5U01CA164974-08
|
$3,131,894
|
$313,189
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
$162,482
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
$50,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-05
|
$8,073,787
|
$403,689
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Molecular Pathogenesis of the Hamartoma Syndromes
|
2P01CA120964-11A1
|
$1,897,687
|
$341,584
|
KWIATKOWSKI, DAVID
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Center of Excellence for High Throughput Proteogenomic Characterization
|
5U24CA210986-03
|
$1,288,045
|
$437,935
|
CARR, STEVEN
|
BROAD INSTITUTE, INC.
|
|
Systematic identification of oncogenic KRAS synthetic lethal interactions
|
5U01CA199253-04
|
$807,776
|
$266,566
|
HAHN, WILLIAM
|
BROAD INSTITUTE, INC.
|
|
The novel PRMT5-substrate adaptor interface provides a therapeutic target in MTAP null tumors
|
1F32CA232543-01
|
$58,654
|
$58,654
|
MULVANEY, KATHLEEN
|
BROAD INSTITUTE, INC.
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-05
|
$1,187,291
|
$29,682
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
IRF2BP2 modification by Cdk5 modulates interferon-gamma response tumor PD-L1 level
|
5R03CA219725-02
|
$80,000
|
$40,000
|
PETROSIUTE, AGNE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting pancreatic cancers metabolic addiction to HuR
|
1R37CA227865-01A1
|
$401,484
|
$401,484
|
WINTER, JORDAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Role of CRABP-II in pancreatic cancer metastasis
|
5R03CA201738-02
|
$80,000
|
$80,000
|
YU, SHUILIANG
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Predicting the diagnosis of pancreatic cancer by leveraging big data
|
1R21CA220073-01A1
|
$203,197
|
$203,197
|
JEON, CHRISTIE
|
CEDARS-SINAI MEDICAL CENTER
|
|
FrostBite - A Unique Catheter for Endoscopic Cryoablation
|
5R44CA183265-03
|
$737,450
|
$737,450
|
BAUST, J
|
CELL PRESERVATION SERVICES, INC.
|
|
Thrombin-dependent mechanisms of pancreatic ductal adenocarcinoma disease
|
5R01CA211098-02
|
$417,066
|
$417,066
|
FLICK, MATTHEW
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers
|
5R44CA210770-03
|
$570,035
|
$570,035
|
PEREZ, KRISTY
|
CIVATECH ONCOLOGY, INC.
|
|
Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer
|
1R44CA224472-01A1
|
$298,791
|
$298,791
|
SUREBAN, SRIPATHI
|
COARE HOLDINGS, INC.
|
|
2/2 Partnership to Study Racial/Ethnic Differences in GI Cancer Biology
|
5P20CA192996-04
|
$154,589
|
$100,483
|
MCCOMBIE, WILLIAM
|
COLD SPRING HARBOR LABORATORY
|
|
Preclinical Models for Cancer Therapeutic Development
|
5R50CA211506-03
|
$174,117
|
$174,117
|
PARK, YOUNGKYU
|
COLD SPRING HARBOR LABORATORY
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
2P01CA013106-46A1
|
$4,537,433
|
$272,246
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity
|
1U01CA224013-01
|
$881,016
|
$881,016
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL Cancer Center Support Grant
|
5P30CA045508-31
|
$4,371,458
|
$1,049,150
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response
|
5R01CA188134-02
|
$615,683
|
$615,683
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
Total relevant funding to Pancreas for this search: $182,103,222
|